Efficacy of a nasal spray containing Iota-carrageenan in the costexposure crophylaxis of COVID-19 in hospital personnel dedicated to patients care with COVID-19 disease

Autores
Figueroa, Juan Manuel; Lombardo, Mónica Edith; Dogliotti, Ariel; Flynn, Luis Pedro; Giugliano, Robert; Simonelli, Guido; Valentini, Ricardo; Ramos, Agñel; Romano, Pablo; Marcote, Marcelo; Michelini, Alicia; Salvado, Alejandro; Sykora, Emilio; Kniz, Cecilia; Kobelinsky, Marcelo; Salzberg, David Manuel; Jerusalinsky, Diana Alicia; Uchitel, Osvaldo Daniel
Año de publicación
2021
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Background: Iota-Carrageenan (I-C) is a sulfate polysaccharide synthesized by red algae, with demonstrated antiviral activity and clinical efficacy as nasal spray in the treatment of common cold. In vitro, I-C inhibits SARS-CoV-2 infection in cell culture. Research Question: Can a nasal spray with Iota-Carrageenan be useful in the prophylaxis of COVID-19 in health care workers managing patients with COVID-19 disease? Study Design and Methods: This is a pilot pragmatic multicenter, randomized, double-blind, placebo-controlled study assessing the use of a nasal spray containing I-C in the prophylaxis of COVID-19 in hospital personnel dedicated to care of COVID-19 patients. Clinically healthy physicians, nurses, kinesiologists and other health care providers managing patients hospitalized for COVID-19 were assigned in a 1:1 ratio to receive four daily doses of I-C spray or placebo for 21 days. The primary end point was clinical COVID-19, as confirmed by reverse transcriptase polymerase chain reaction testing, over a period of 21 days. The trial is registered at ClinicalTrials.gov (NCT04521322). Results: A total of 394 individuals were randomly assigned to receive I-C or placebo. Both treatment groups had similar baseline characteristics. The incidence of COVID-19 differs significantly between subjects receiving the nasal spray with I-C (2 of 196 [1.0%]) and those receiving placebo (10 of 198 [5.0%]). Relative risk reduction: 79.8% (95% CI 5.3 to 95.4; p=0.03). Absolute risk reduction: 4% (95% CI 0.6 to 7.4). Interpretation: In this pilot study a nasal spray with I-C showed significant efficacy in preventing COVID-19 in health care workers managing patients with COVID-19 disease. Clinical Trials Registration: NCT04521322.
Fil: Figueroa, Juan Manuel. Instituto de Ciencia y Tecnología Dr. César Milstein; Argentina
Fil: Lombardo, Mónica Edith. Nobeltri S.r.l; Argentina. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina
Fil: Dogliotti, Ariel. Instituto Cardiovascular de Rosario; Argentina
Fil: Flynn, Luis Pedro. Sanatorio de Niños de Rosario; Argentina
Fil: Giugliano, Robert. Harvard Medical School; Estados Unidos
Fil: Simonelli, Guido. McGill University. Montreal Neurological Institute and Hospital; Canadá
Fil: Valentini, Ricardo. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina
Fil: Ramos, Agñel. Sanatorio Parque de Rosario; Argentina
Fil: Romano, Pablo. Clínica y Maternidad Santa Isabel; Argentina
Fil: Marcote, Marcelo. Gobierno de la Provincia de Buenos Aires. Hospital Interzonal General de Agudos Presidente Peron; Argentina
Fil: Michelini, Alicia. Hospital Pediátrico Avelino Castelán; Argentina
Fil: Salvado, Alejandro. Hospital Británico de Buenos Aires; Argentina
Fil: Sykora, Emilio. Clínica Privada Monte Grande; Argentina
Fil: Kniz, Cecilia. Gobierno de la Provincia de Chaco. Hospital 4 de Junio Ramón Carrillo; Argentina
Fil: Kobelinsky, Marcelo. Clínica Modelo de Morón; Argentina
Fil: Salzberg, David Manuel. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Dr. Teodoro Álvarez"; Argentina
Fil: Jerusalinsky, Diana Alicia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Biología Celular y Neurociencia "Prof. Eduardo de Robertis". Universidad de Buenos Aires. Facultad de Medicina. Instituto de Biología Celular y Neurociencia; Argentina
Fil: Uchitel, Osvaldo Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Fisiología, Biología Molecular y Neurociencias. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Fisiología, Biología Molecular y Neurociencias; Argentina
Materia
COVID-19
HOSPITAL WORKERS
NASAL
PROPHYLAXIS
SPRAY
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/148839
Acceder
id CONICETDig_8218d4c2cf3adc18ce48938e3bb1db6a
oai_identifier_str oai:ri.conicet.gov.ar:11336/148839
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Efficacy of a nasal spray containing Iota-carrageenan in the costexposure crophylaxis of COVID-19 in hospital personnel dedicated to patients care with COVID-19 diseaseFigueroa, Juan ManuelLombardo, Mónica EdithDogliotti, ArielFlynn, Luis PedroGiugliano, RobertSimonelli, GuidoValentini, RicardoRamos, AgñelRomano, PabloMarcote, MarceloMichelini, AliciaSalvado, AlejandroSykora, EmilioKniz, CeciliaKobelinsky, MarceloSalzberg, David ManuelJerusalinsky, Diana AliciaUchitel, Osvaldo DanielCOVID-19HOSPITAL WORKERSNASALPROPHYLAXISSPRAYhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Background: Iota-Carrageenan (I-C) is a sulfate polysaccharide synthesized by red algae, with demonstrated antiviral activity and clinical efficacy as nasal spray in the treatment of common cold. In vitro, I-C inhibits SARS-CoV-2 infection in cell culture. Research Question: Can a nasal spray with Iota-Carrageenan be useful in the prophylaxis of COVID-19 in health care workers managing patients with COVID-19 disease? Study Design and Methods: This is a pilot pragmatic multicenter, randomized, double-blind, placebo-controlled study assessing the use of a nasal spray containing I-C in the prophylaxis of COVID-19 in hospital personnel dedicated to care of COVID-19 patients. Clinically healthy physicians, nurses, kinesiologists and other health care providers managing patients hospitalized for COVID-19 were assigned in a 1:1 ratio to receive four daily doses of I-C spray or placebo for 21 days. The primary end point was clinical COVID-19, as confirmed by reverse transcriptase polymerase chain reaction testing, over a period of 21 days. The trial is registered at ClinicalTrials.gov (NCT04521322). Results: A total of 394 individuals were randomly assigned to receive I-C or placebo. Both treatment groups had similar baseline characteristics. The incidence of COVID-19 differs significantly between subjects receiving the nasal spray with I-C (2 of 196 [1.0%]) and those receiving placebo (10 of 198 [5.0%]). Relative risk reduction: 79.8% (95% CI 5.3 to 95.4; p=0.03). Absolute risk reduction: 4% (95% CI 0.6 to 7.4). Interpretation: In this pilot study a nasal spray with I-C showed significant efficacy in preventing COVID-19 in health care workers managing patients with COVID-19 disease. Clinical Trials Registration: NCT04521322.Fil: Figueroa, Juan Manuel. Instituto de Ciencia y Tecnología Dr. César Milstein; ArgentinaFil: Lombardo, Mónica Edith. Nobeltri S.r.l; Argentina. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; ArgentinaFil: Dogliotti, Ariel. Instituto Cardiovascular de Rosario; ArgentinaFil: Flynn, Luis Pedro. Sanatorio de Niños de Rosario; ArgentinaFil: Giugliano, Robert. Harvard Medical School; Estados UnidosFil: Simonelli, Guido. McGill University. Montreal Neurological Institute and Hospital; CanadáFil: Valentini, Ricardo. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; ArgentinaFil: Ramos, Agñel. Sanatorio Parque de Rosario; ArgentinaFil: Romano, Pablo. Clínica y Maternidad Santa Isabel; ArgentinaFil: Marcote, Marcelo. Gobierno de la Provincia de Buenos Aires. Hospital Interzonal General de Agudos Presidente Peron; ArgentinaFil: Michelini, Alicia. Hospital Pediátrico Avelino Castelán; ArgentinaFil: Salvado, Alejandro. Hospital Británico de Buenos Aires; ArgentinaFil: Sykora, Emilio. Clínica Privada Monte Grande; ArgentinaFil: Kniz, Cecilia. Gobierno de la Provincia de Chaco. Hospital 4 de Junio Ramón Carrillo; ArgentinaFil: Kobelinsky, Marcelo. Clínica Modelo de Morón; ArgentinaFil: Salzberg, David Manuel. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Dr. Teodoro Álvarez"; ArgentinaFil: Jerusalinsky, Diana Alicia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Biología Celular y Neurociencia "Prof. Eduardo de Robertis". Universidad de Buenos Aires. Facultad de Medicina. Instituto de Biología Celular y Neurociencia; ArgentinaFil: Uchitel, Osvaldo Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Fisiología, Biología Molecular y Neurociencias. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Fisiología, Biología Molecular y Neurociencias; ArgentinaDove Press2021-10-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/148839Figueroa, Juan Manuel; Lombardo, Mónica Edith; Dogliotti, Ariel; Flynn, Luis Pedro; Giugliano, Robert; et al.; Efficacy of a nasal spray containing Iota-carrageenan in the costexposure crophylaxis of COVID-19 in hospital personnel dedicated to patients care with COVID-19 disease; Dove Press; International Journal of General Medicine; 14; 1-10-2021; 6277-62861178-7074CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.dovepress.com/efficacy-of-a-nasal-spray-containing-iota-carrageenan-in-the-postexpos-peer-reviewed-fulltext-article-IJGMinfo:eu-repo/semantics/altIdentifier/doi/10.2147/IJGM.S328486info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:31:11Zoai:ri.conicet.gov.ar:11336/148839instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:31:11.521CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Efficacy of a nasal spray containing Iota-carrageenan in the costexposure crophylaxis of COVID-19 in hospital personnel dedicated to patients care with COVID-19 disease
title Efficacy of a nasal spray containing Iota-carrageenan in the costexposure crophylaxis of COVID-19 in hospital personnel dedicated to patients care with COVID-19 disease
spellingShingle Efficacy of a nasal spray containing Iota-carrageenan in the costexposure crophylaxis of COVID-19 in hospital personnel dedicated to patients care with COVID-19 disease
Figueroa, Juan Manuel
COVID-19
HOSPITAL WORKERS
NASAL
PROPHYLAXIS
SPRAY
title_short Efficacy of a nasal spray containing Iota-carrageenan in the costexposure crophylaxis of COVID-19 in hospital personnel dedicated to patients care with COVID-19 disease
title_full Efficacy of a nasal spray containing Iota-carrageenan in the costexposure crophylaxis of COVID-19 in hospital personnel dedicated to patients care with COVID-19 disease
title_fullStr Efficacy of a nasal spray containing Iota-carrageenan in the costexposure crophylaxis of COVID-19 in hospital personnel dedicated to patients care with COVID-19 disease
title_full_unstemmed Efficacy of a nasal spray containing Iota-carrageenan in the costexposure crophylaxis of COVID-19 in hospital personnel dedicated to patients care with COVID-19 disease
title_sort Efficacy of a nasal spray containing Iota-carrageenan in the costexposure crophylaxis of COVID-19 in hospital personnel dedicated to patients care with COVID-19 disease
dc.creator.none.fl_str_mv Figueroa, Juan Manuel
Lombardo, Mónica Edith
Dogliotti, Ariel
Flynn, Luis Pedro
Giugliano, Robert
Simonelli, Guido
Valentini, Ricardo
Ramos, Agñel
Romano, Pablo
Marcote, Marcelo
Michelini, Alicia
Salvado, Alejandro
Sykora, Emilio
Kniz, Cecilia
Kobelinsky, Marcelo
Salzberg, David Manuel
Jerusalinsky, Diana Alicia
Uchitel, Osvaldo Daniel
author Figueroa, Juan Manuel
author_facet Figueroa, Juan Manuel
Lombardo, Mónica Edith
Dogliotti, Ariel
Flynn, Luis Pedro
Giugliano, Robert
Simonelli, Guido
Valentini, Ricardo
Ramos, Agñel
Romano, Pablo
Marcote, Marcelo
Michelini, Alicia
Salvado, Alejandro
Sykora, Emilio
Kniz, Cecilia
Kobelinsky, Marcelo
Salzberg, David Manuel
Jerusalinsky, Diana Alicia
Uchitel, Osvaldo Daniel
author_role author
author2 Lombardo, Mónica Edith
Dogliotti, Ariel
Flynn, Luis Pedro
Giugliano, Robert
Simonelli, Guido
Valentini, Ricardo
Ramos, Agñel
Romano, Pablo
Marcote, Marcelo
Michelini, Alicia
Salvado, Alejandro
Sykora, Emilio
Kniz, Cecilia
Kobelinsky, Marcelo
Salzberg, David Manuel
Jerusalinsky, Diana Alicia
Uchitel, Osvaldo Daniel
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv COVID-19
HOSPITAL WORKERS
NASAL
PROPHYLAXIS
SPRAY
topic COVID-19
HOSPITAL WORKERS
NASAL
PROPHYLAXIS
SPRAY
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Background: Iota-Carrageenan (I-C) is a sulfate polysaccharide synthesized by red algae, with demonstrated antiviral activity and clinical efficacy as nasal spray in the treatment of common cold. In vitro, I-C inhibits SARS-CoV-2 infection in cell culture. Research Question: Can a nasal spray with Iota-Carrageenan be useful in the prophylaxis of COVID-19 in health care workers managing patients with COVID-19 disease? Study Design and Methods: This is a pilot pragmatic multicenter, randomized, double-blind, placebo-controlled study assessing the use of a nasal spray containing I-C in the prophylaxis of COVID-19 in hospital personnel dedicated to care of COVID-19 patients. Clinically healthy physicians, nurses, kinesiologists and other health care providers managing patients hospitalized for COVID-19 were assigned in a 1:1 ratio to receive four daily doses of I-C spray or placebo for 21 days. The primary end point was clinical COVID-19, as confirmed by reverse transcriptase polymerase chain reaction testing, over a period of 21 days. The trial is registered at ClinicalTrials.gov (NCT04521322). Results: A total of 394 individuals were randomly assigned to receive I-C or placebo. Both treatment groups had similar baseline characteristics. The incidence of COVID-19 differs significantly between subjects receiving the nasal spray with I-C (2 of 196 [1.0%]) and those receiving placebo (10 of 198 [5.0%]). Relative risk reduction: 79.8% (95% CI 5.3 to 95.4; p=0.03). Absolute risk reduction: 4% (95% CI 0.6 to 7.4). Interpretation: In this pilot study a nasal spray with I-C showed significant efficacy in preventing COVID-19 in health care workers managing patients with COVID-19 disease. Clinical Trials Registration: NCT04521322.
Fil: Figueroa, Juan Manuel. Instituto de Ciencia y Tecnología Dr. César Milstein; Argentina
Fil: Lombardo, Mónica Edith. Nobeltri S.r.l; Argentina. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina
Fil: Dogliotti, Ariel. Instituto Cardiovascular de Rosario; Argentina
Fil: Flynn, Luis Pedro. Sanatorio de Niños de Rosario; Argentina
Fil: Giugliano, Robert. Harvard Medical School; Estados Unidos
Fil: Simonelli, Guido. McGill University. Montreal Neurological Institute and Hospital; Canadá
Fil: Valentini, Ricardo. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina
Fil: Ramos, Agñel. Sanatorio Parque de Rosario; Argentina
Fil: Romano, Pablo. Clínica y Maternidad Santa Isabel; Argentina
Fil: Marcote, Marcelo. Gobierno de la Provincia de Buenos Aires. Hospital Interzonal General de Agudos Presidente Peron; Argentina
Fil: Michelini, Alicia. Hospital Pediátrico Avelino Castelán; Argentina
Fil: Salvado, Alejandro. Hospital Británico de Buenos Aires; Argentina
Fil: Sykora, Emilio. Clínica Privada Monte Grande; Argentina
Fil: Kniz, Cecilia. Gobierno de la Provincia de Chaco. Hospital 4 de Junio Ramón Carrillo; Argentina
Fil: Kobelinsky, Marcelo. Clínica Modelo de Morón; Argentina
Fil: Salzberg, David Manuel. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Dr. Teodoro Álvarez"; Argentina
Fil: Jerusalinsky, Diana Alicia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Biología Celular y Neurociencia "Prof. Eduardo de Robertis". Universidad de Buenos Aires. Facultad de Medicina. Instituto de Biología Celular y Neurociencia; Argentina
Fil: Uchitel, Osvaldo Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Fisiología, Biología Molecular y Neurociencias. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Fisiología, Biología Molecular y Neurociencias; Argentina
description Background: Iota-Carrageenan (I-C) is a sulfate polysaccharide synthesized by red algae, with demonstrated antiviral activity and clinical efficacy as nasal spray in the treatment of common cold. In vitro, I-C inhibits SARS-CoV-2 infection in cell culture. Research Question: Can a nasal spray with Iota-Carrageenan be useful in the prophylaxis of COVID-19 in health care workers managing patients with COVID-19 disease? Study Design and Methods: This is a pilot pragmatic multicenter, randomized, double-blind, placebo-controlled study assessing the use of a nasal spray containing I-C in the prophylaxis of COVID-19 in hospital personnel dedicated to care of COVID-19 patients. Clinically healthy physicians, nurses, kinesiologists and other health care providers managing patients hospitalized for COVID-19 were assigned in a 1:1 ratio to receive four daily doses of I-C spray or placebo for 21 days. The primary end point was clinical COVID-19, as confirmed by reverse transcriptase polymerase chain reaction testing, over a period of 21 days. The trial is registered at ClinicalTrials.gov (NCT04521322). Results: A total of 394 individuals were randomly assigned to receive I-C or placebo. Both treatment groups had similar baseline characteristics. The incidence of COVID-19 differs significantly between subjects receiving the nasal spray with I-C (2 of 196 [1.0%]) and those receiving placebo (10 of 198 [5.0%]). Relative risk reduction: 79.8% (95% CI 5.3 to 95.4; p=0.03). Absolute risk reduction: 4% (95% CI 0.6 to 7.4). Interpretation: In this pilot study a nasal spray with I-C showed significant efficacy in preventing COVID-19 in health care workers managing patients with COVID-19 disease. Clinical Trials Registration: NCT04521322.
publishDate 2021
dc.date.none.fl_str_mv 2021-10-01
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/148839
Figueroa, Juan Manuel; Lombardo, Mónica Edith; Dogliotti, Ariel; Flynn, Luis Pedro; Giugliano, Robert; et al.; Efficacy of a nasal spray containing Iota-carrageenan in the costexposure crophylaxis of COVID-19 in hospital personnel dedicated to patients care with COVID-19 disease; Dove Press; International Journal of General Medicine; 14; 1-10-2021; 6277-6286
1178-7074
CONICET Digital
CONICET
url http://hdl.handle.net/11336/148839
identifier_str_mv Figueroa, Juan Manuel; Lombardo, Mónica Edith; Dogliotti, Ariel; Flynn, Luis Pedro; Giugliano, Robert; et al.; Efficacy of a nasal spray containing Iota-carrageenan in the costexposure crophylaxis of COVID-19 in hospital personnel dedicated to patients care with COVID-19 disease; Dove Press; International Journal of General Medicine; 14; 1-10-2021; 6277-6286
1178-7074
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.dovepress.com/efficacy-of-a-nasal-spray-containing-iota-carrageenan-in-the-postexpos-peer-reviewed-fulltext-article-IJGM
info:eu-repo/semantics/altIdentifier/doi/10.2147/IJGM.S328486
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Dove Press
publisher.none.fl_str_mv Dove Press
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846781913364168704
score 12.982451

Publicaciones similares